ClinicalTrials.gg
CompletedNCT02792829Updated Mar 14, 2019Results posted

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

A Phase 1 interventional study of Lenvatinib in Healthy Volunteers, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-14.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study will be conducted in adult healthy participants and will consist of two phases: Prerandomization and Randomization. The Prerandomization Phase will consist of 2 periods: a Screening Period and a Baseline Period. The Randomization Phase will consist of 2 Periods (each 6 days long) separated by a 1-day long Baseline Period and End of Treatment (EOT) Period. A total of 60 participants will be enrolled into one of three arms. Arms 1 and 3 consist of 2 sequences, and Arm 2 consists of 4 sequences (as this is an incomplete block design with 2 factors [number of capsules and whether water or apple juice is used as vehicle]). Each participant will be randomized into one of 8 sequences.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Bioavailability of Lenvatinib suspension
  • Palatability of Lenvatinib suspension
  • Lenvatinib
  • Lenvima
  • E7080
  • Capsule formulation
  • Healthy volunteers
03

In context

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female participants age greater than or equal to 18 years and less than or equal to 55 years old at time of
  2. Nonsmokers or smokers who smoke no more than 10 cigarettes per day
  3. greater than or equal to 18 and less than or equal to 32 kg/m2 at screening
  4. Adequate liver function, defined as: less than or equal to 1.5 X the (ULN), (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) less than or equal to 1.5 X ULN
  5. Adequate renal function defined as greater than 70 mL/min calculated using the Cockcroft and Gault formula
  6. Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of 25 IU/L, or equivalent units of B-hCG. A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  7. All females will be considered to be of unless they are (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)
  8. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the participant must agree to use a double-barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
  9. Male participants must have had a successful vasectomy (confirmed azoospermia), or they and their female partners must meet the criteria above (ie, not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study period and for 30 days after study drug discontinuation.
  10. Provide written informed consent
  11. Willing and able to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria:

  1. illness that requires medical treatment within 8 weeks prior, or a clinically significant infection that requires medical treatment within 4 weeks prior to dosing
  2. Evidence of disease that may influence the outcome of the study, within 4 weeks prior to dosing; eg, psychiatric disorders and disorders of the gastrointestinal (GI) tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism
  3. Any history of surgery that may affect PK profiles of lenvatinib eg, hepatectomy, nephrotomy, digestive organ resection, at screening or baseline
  4. Any clinically abnormal symptom or organ impairment found by medical history, physical examinations, vital signs, (ECG) finding, or laboratory test results that requires medical treatment at screening or baseline
  5. Prolonged interval (QTcF greater than 450 ms) demonstrated on ECG at screening or baseline
  6. Known history of clinically significant drug allergy at Screening or Baseline
  7. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening or Baseline
  8. Known history of sensitivity to any of the components of the test products
  9. Known to be (HIV) positive at screening
  10. Active viral hepatitis (A, B, or C) as demonstrated by positive serology at screening
  11. History of drug or alcohol dependency or abuse within the 2 years prior to screening, or those who have a positive urine drug test or breath alcohol test at Screening or Baseline
  12. Engagement in strenuous exercise within 2 weeks prior to check-in (eg, marathon runners, weight lifters)
  13. Any medical or other condition that would make the participant in the opinion of the investigator or sponsor, unsuitable for the study or who, in the opinion of the investigator, are not likely to complete the study for any reason
  14. Intake of herbal preparations containing St. John's Wort within 4 weeks prior to dosing
  15. Use of prescription drugs within 4 weeks prior to dosing
  16. Intake of over-the-counter (OTC) medications within 2 weeks prior to dosing
  17. Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week prior to dosing
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Lenvatinib 11 mg (suspension formulation)

    Arm 1 will have 2 sequences: 1. Sequence 1 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg) 2. Sequence 2 - Treatment Period 1: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg)

    Drug: Lenvatinib

  • Experimental
    Lenvatinib 11 mg (2 vs 5 capsules)

    Arm 2 will have 4 sequences: 1. Sequence 3 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg) WATER; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg) APPLE JUICE 2. Sequence 4 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER 3. Sequence 5 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE 4. Sequence 6 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) WATER

    Drug: Lenvatinib

  • Experimental
    Lenvatinib 23 mg

    Arm 3 will have 2 sequences: 1. Sequence 7 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation 2. Sequence 8 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation

    Drug: Lenvatinib

Interventions

  • All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.

    Also known as: Lenvima; E7080

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t))

    Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) method using a previously validated assay. The lower limit of quantitation (LLOQ) was 0.25 ng/mL. Plasma pharmacokinetics (PK) data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of AUC(0-t), which were then summarized as the mean and standard deviation for all participants and expressed as hours·nanogram/milliliter (hr·ng/mL).

    Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)

  2. Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUC(0-inf))

    Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-inf), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.

    Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)

  3. Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24))

    Blood samples were collected during each Treatment Period at predose up to 24 hours post dose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-24), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.

    Time frame: Treatment Period 1: Predose up to 24 hours post dose

  4. Area Under the Plasma Concentration-Time Curve From Zero to 72 Hours (AUC(0-72))

    Blood samples were collected during each Treatment Period at predose up to 72 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-72), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.

    Time frame: Treatment Period 1: Predose up to 72 hours postdose

  5. Apparent Clearance (CL/F)

    Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the CL/F, which were then summarized as the mean and standard deviation for all participants and expressed as liters/hour.

    Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)

  6. Apparent Volume of Distribution (Vz/F)

    Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the Vz/F, which were then summarized as the mean and standard deviation for all participants and expressed in liters (L).

    Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)

  7. Maximum Concentration (Cmax) of Lenvatinib in Plasma

    Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of Cmax, which were then summarized as the mean and standard deviation for all participants and expressed as nanograms/milliliter (ng/mL).

    Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)

  8. Time Prior to the First Measureable Concentration of Lenvatinib (Tlag)

    Tlag was defined as the time delay between drug administration and the onset of drug absorption. Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of tlag, which were then summarized as the median and full range for all participants and expressed in hours.

    Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)

  9. Time to Maximum Plasma Concentration (Tmax)

    Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of tmax, which were then summarized as the median and full range for all participants and expressed in hours.

    Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)

  10. Terminal Elimination Phase Half-life (t1/2)

    Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of t1/2, which were then summarized as the median and full range for all participants and expressed in hours.

    Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)

  11. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib

    Safety assessment consisted on monitoring and recording all treatment-emergent adverse events (TEAEs) and SAEs; as well as laboratory evaluations for hematology, blood chemistry, and urine values; periodic measurement of vital signs, electrocardiograms (ECGs); and physical examinations. A TEAE was defined as an adverse events that: 1) emerged during treatment and up to 7 days from the last treatment, having been absent before treatment or at baseline, 2) reemerged during treatment, having been present at Baseline but stopped before treatment, or 3) worsened in severity during treatment relative to the state before treatment, when continuous.

    Time frame: From date of first dose of study treatment to date of last dose of study treatment, up to approximately 2 months 10 days

Secondary outcomes

  1. Summary Scores for Palatability of Lenvatinib

    A hedonic Visual Analog Scale (VAS) was used to assess taste likability or "palatability" between a) lenvatinib suspension formulated with water versus the capsule formulation, b) a lenvatinib suspension formulated with with apple juice versus one formulated with water, and c) a lenvatinib suspension formulated with water administered 23 hours versus 2 hours after preparation. All participants selected one face based on flavor, smell, sweetness, acidity, saltiness, bitterness, and texture or mouth feel for each formulation they consumed. Each face had an associated score (1: Very Bad (angry face), 2: Bad (sad face), 3: Maybe Good or Maybe Bad (neutral face), 4: Good (smiling face), 5: Very Good (laughing face)). The VAS hedonic scale scores were summarized using descriptive statistics separately for each arm by formulation (Arm 1), number of capsules (2 vs 5 capsules) and preparation type (water vs apple juice) (Arm 2), and time of administration relative to preparation (Arm 3).

    Time frame: Treatment Period 1, Day 1 (Visit 2); Treatment Period 2, Day 8 (Visit 8)

07

Results

Posted Mar 14, 2019

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneArm 1: Lenvatinib 11 mg: Suspension+ Capsules (CAP)Arm 1: Lenvatinib 11 mg: CAP+ SuspensionArm 2:Lenvatinib 11mg Suspension:5 CAP-Water+2 Cap-Apple JuiceArm 2:Lenvatinib 11mg Suspension:5 CAP-Apple Juice+2 CAP-WaterArm 2:Lenvatinib 11mg Suspension:2 CAP-Water+5 CAP-Apple JuiceArm 2:Lenvatinib 11mg Suspension:2 CAP-Apple Juice+5 CAP-WaterArm 3:Lenvatinib 23mg Suspension Taken at:23 Hours+2 HoursArm 3:Lenvatinib 23mg Suspension Taken at:2 Hours+23 Hours
Started101055551010
Completed101055551010
Not completed00000000
Wash Out Period
Participant flow — Wash Out Period
MilestoneArm 1: Lenvatinib 11 mg: Suspension+ Capsules (CAP)Arm 1: Lenvatinib 11 mg: CAP+ SuspensionArm 2:Lenvatinib 11mg Suspension:5 CAP-Water+2 Cap-Apple JuiceArm 2:Lenvatinib 11mg Suspension:5 CAP-Apple Juice+2 CAP-WaterArm 2:Lenvatinib 11mg Suspension:2 CAP-Water+5 CAP-Apple JuiceArm 2:Lenvatinib 11mg Suspension:2 CAP-Apple Juice+5 CAP-WaterArm 3:Lenvatinib 23mg Suspension Taken at:23 Hours+2 HoursArm 3:Lenvatinib 23mg Suspension Taken at:2 Hours+23 Hours
Started101055551010
Completed101055551010
Not completed00000000
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneArm 1: Lenvatinib 11 mg: Suspension+ Capsules (CAP)Arm 1: Lenvatinib 11 mg: CAP+ SuspensionArm 2:Lenvatinib 11mg Suspension:5 CAP-Water+2 Cap-Apple JuiceArm 2:Lenvatinib 11mg Suspension:5 CAP-Apple Juice+2 CAP-WaterArm 2:Lenvatinib 11mg Suspension:2 CAP-Water+5 CAP-Apple JuiceArm 2:Lenvatinib 11mg Suspension:2 CAP-Apple Juice+5 CAP-WaterArm 3:Lenvatinib 23mg Suspension Taken at:23 Hours+2 HoursArm 3:Lenvatinib 23mg Suspension Taken at:2 Hours+23 Hours
Started101055551010
Completed109554598
Not completed01001012
Withdrew: Non compliance with alcohol prohibition01000000
Withdrew: Adverse event00001011
Withdrew: Use of proscribed medications00000001

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t))

Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) method using a previously validated assay. The lower limit of quantitation (LLOQ) was 0.25 ng/mL. Plasma pharmacokinetics (PK) data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of AUC(0-t), which were then summarized as the mean and standard deviation for all participants and expressed as hours·nanogram/milliliter (hr·ng/mL).

Time frame:
Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Reported as:
Mean · hr·ng/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t))
hr·ng/mLArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t))1330 ± 4521340 ± 4821020 ± 1721500 ± 7061340 ± 5191010 ± 1603010 ± 9193210 ± 1040
PrimaryArea Under the Plasma Concentration-Time Curve From Zero to Infinity (AUC(0-inf))

Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-inf), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.

Time frame:
Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Reported as:
Mean · hr·ng/mL
Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUC(0-inf))
hr·ng/mLArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUC(0-inf))1360 ± 4561360 ± 4901040 ± 1771530 ± 7201370 ± 5321030 ± 1612970 ± 9103240 ± 1050
PrimaryArea Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24))

Blood samples were collected during each Treatment Period at predose up to 24 hours post dose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-24), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.

Time frame:
Treatment Period 1: Predose up to 24 hours post dose
Reported as:
Mean · h·ng/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24))
h·ng/mLArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24))1060 ± 3771050 ± 383815 ± 1361150 ± 5641070 ± 415804 ± 1362540 ± 7852720 ± 858
PrimaryArea Under the Plasma Concentration-Time Curve From Zero to 72 Hours (AUC(0-72))

Blood samples were collected during each Treatment Period at predose up to 72 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-72), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.

Time frame:
Treatment Period 1: Predose up to 72 hours postdose
Reported as:
Mean · hr·ng/mL
Area Under the Plasma Concentration-Time Curve From Zero to 72 Hours (AUC(0-72))
hr·ng/mLArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
Area Under the Plasma Concentration-Time Curve From Zero to 72 Hours (AUC(0-72))1280 ± 4371290 ± 466987 ± 1641430 ± 6681290 ± 500971 ± 1522930 ± 8873130 ± 1010
PrimaryApparent Clearance (CL/F)

Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the CL/F, which were then summarized as the mean and standard deviation for all participants and expressed as liters/hour.

Time frame:
Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Reported as:
Mean · L/hour
Apparent Clearance (CL/F)
L/hourArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
Apparent Clearance (CL/F)9.34 ± 4.369.47 ± 4.4510.8 ± 1.738.70 ± 3.449.10 ± 3.0710.9 ± 1.618.46 ± 2.657.73 ± 2.19
PrimaryApparent Volume of Distribution (Vz/F)

Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the Vz/F, which were then summarized as the mean and standard deviation for all participants and expressed in liters (L).

Time frame:
Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Reported as:
Mean · Liters
Apparent Volume of Distribution (Vz/F)
LitersArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
Apparent Volume of Distribution (Vz/F)301 ± 159296 ± 123356 ± 74.0317 ± 131312 ± 122360 ± 103247 ± 95.7238 ± 122
PrimaryMaximum Concentration (Cmax) of Lenvatinib in Plasma

Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of Cmax, which were then summarized as the mean and standard deviation for all participants and expressed as nanograms/milliliter (ng/mL).

Time frame:
Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Reported as:
Mean · ng/mL
Maximum Concentration (Cmax) of Lenvatinib in Plasma
ng/mLArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 11 mg Lenvatinib Suspension in Water (2 Hours)
Maximum Concentration (Cmax) of Lenvatinib in Plasma133 ± 52.5126 ± 44.9115 ± 22.9150 ± 65.2138 ± 61.3105 ± 21.2358 ± 128375 ± 134
PrimaryTime Prior to the First Measureable Concentration of Lenvatinib (Tlag)

Tlag was defined as the time delay between drug administration and the onset of drug absorption. Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of tlag, which were then summarized as the median and full range for all participants and expressed in hours.

Time frame:
Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Reported as:
Median · Hours
Time Prior to the First Measureable Concentration of Lenvatinib (Tlag)
HoursArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
Time Prior to the First Measureable Concentration of Lenvatinib (Tlag)0.00 (0.00 to 0.53)0.00 (0.00 to 0.50)0.00 (0.00 to 0.50)0.00 (0.00 to 0.00)0.00 (0.00 to 0.50)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
PrimaryTime to Maximum Plasma Concentration (Tmax)

Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of tmax, which were then summarized as the median and full range for all participants and expressed in hours.

Time frame:
Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Reported as:
Median · Hours
Time to Maximum Plasma Concentration (Tmax)
HoursArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
Time to Maximum Plasma Concentration (Tmax)3.00 (1.00 to 4.00)3.00 (2.00 to 4.00)2.52 (2.00 to 3.00)3.00 (2.00 to 3.00)2.50 (2.00 to 4.00)2.00 (2.00 to 3.00)2.00 (1.00 to 4.00)2.00 (1.00 to 3.00)
PrimaryTerminal Elimination Phase Half-life (t1/2)

Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of t1/2, which were then summarized as the median and full range for all participants and expressed in hours.

Time frame:
Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Reported as:
Mean · Hours
Terminal Elimination Phase Half-life (t1/2)
HoursArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
Terminal Elimination Phase Half-life (t1/2)22.7 ± 6.0922.4 ± 4.6723.2 ± 5.6725.5 ± 4.2724.1 ± 5.0523.1 ± 6.1520.4 ± 4.5121.5 ± 7.35
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib

Safety assessment consisted on monitoring and recording all treatment-emergent adverse events (TEAEs) and SAEs; as well as laboratory evaluations for hematology, blood chemistry, and urine values; periodic measurement of vital signs, electrocardiograms (ECGs); and physical examinations. A TEAE was defined as an adverse events that: 1) emerged during treatment and up to 7 days from the last treatment, having been absent before treatment or at baseline, 2) reemerged during treatment, having been present at Baseline but stopped before treatment, or 3) worsened in severity during treatment relative to the state before treatment, when continuous.

Time frame:
From date of first dose of study treatment to date of last dose of study treatment, up to approximately 2 months 10 days
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib
ParticipantsArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
TEAEs46124434
Treatment-related TEAEs46012132
Severe TEAEs00000000
Serious TEAEs00000000
SecondarySummary Scores for Palatability of Lenvatinib

A hedonic Visual Analog Scale (VAS) was used to assess taste likability or "palatability" between a) lenvatinib suspension formulated with water versus the capsule formulation, b) a lenvatinib suspension formulated with with apple juice versus one formulated with water, and c) a lenvatinib suspension formulated with water administered 23 hours versus 2 hours after preparation. All participants selected one face based on flavor, smell, sweetness, acidity, saltiness, bitterness, and texture or mouth feel for each formulation they consumed. Each face had an associated score (1: Very Bad (angry face), 2: Bad (sad face), 3: Maybe Good or Maybe Bad (neutral face), 4: Good (smiling face), 5: Very Good (laughing face)). The VAS hedonic scale scores were summarized using descriptive statistics separately for each arm by formulation (Arm 1), number of capsules (2 vs 5 capsules) and preparation type (water vs apple juice) (Arm 2), and time of administration relative to preparation (Arm 3).

Time frame:
Treatment Period 1, Day 1 (Visit 2); Treatment Period 2, Day 8 (Visit 8)
Reported as:
Median · Score on a scale
Summary Scores for Palatability of Lenvatinib
Score on a scaleArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterLenvatinib 11 mg (Suspension of 5 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water)Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
Flavor Score3.0 (1 to 5)4.0 (2 to 5)3.0 (1 to 5)4.0 (2 to 5)2.5 (1 to 4)4.0 (1 to 5)2.0 (1 to 5)2.0 (1 to 4)
Smell Score4.0 (3 to 5)4.0 (2 to 5)3.5 (2 to 5)4.0 (3 to 4)4.0 (3 to 5)4.0 (3 to 5)3.0 (1 to 5)3.0 (2 to 5)
Sweetness Score3.0 (1 to 5)3.0 (1 to 5)3.0 (1 to 4)4.0 (2 to 5)2.0 (1 to 4)4.0 (2 to 5)2.0 (1 to 4)2.0 (1 to 4)
Acidity Score3.0 (1 to 5)4.0 (2 to 5)3.0 (1 to 5)3.0 (2 to 4)2.5 (1 to 4)4.0 (2 to 5)3.0 (1 to 5)3.0 (1 to 4)
Saltiness Score3.0 (2 to 5)4.0 (1 to 5)3.0 (1 to 4)4.0 (1 to 5)3.0 (2 to 5)4.0 (2 to 5)3.0 (2 to 5)4.0 (1 to 5)
Bitterness Score3.0 (1 to 5)3.5 (1 to 5)3.0 (1 to 5)3.0 (2 to 4)3.0 (1 to 5)3.5 (2 to 5)3.0 (1 to 5)2.0 (1 to 5)
Texture or Mouth feel Score3.0 (1 to 5)3.5 (2 to 5)2.0 (1 to 4)4.0 (1 to 5)3.0 (1 to 5)4.0 (2 to 5)2.0 (1 to 4)2.0 (1 to 5)

Adverse events

Collected over From date of first dose of study treatment to date of last dose of study treatment, up to approximately 2 months 10 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: 11 mg Lenvatinib Suspension in Water0/19 (0%)0/19 (0%)4/19 (21.1%)
Arm 1: 11 mg Lenvatinib Capsule With Water0/20 (0%)0/20 (0%)6/20 (30%)
Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water)0/10 (0%)0/10 (0%)1/10 (10%)
Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice)0/9 (0%)0/9 (0%)2/9 (22.2%)
Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water)0/10 (0%)0/10 (0%)4/10 (40%)
Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice)0/10 (0%)0/10 (0%)4/10 (40%)
Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)0/18 (0%)0/18 (0%)3/18 (16.7%)
Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)0/19 (0%)0/19 (0%)4/19 (21.1%)
Most frequent other events
Showing 10 of 29
Most frequent other events
EventArm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)
HeadacheNervous system disorders1/191/200/101/90/100/102/180/19
Heart rate decreasedInvestigations0/190/200/101/90/101/100/180/19
DiarrhoeaGastrointestinal disorders0/191/200/100/90/101/100/180/19
Blood glucose decreasedInvestigations0/190/200/100/91/101/100/180/19
Blood phosphorus decreasedInvestigations0/190/200/100/91/100/100/180/19
Blood pressure increasedInvestigations0/190/200/100/91/100/100/180/19
Urine analysis abnormalInvestigations0/190/200/100/91/101/100/180/19
ErythemaSkin and subcutaneous tissue disorders0/190/201/100/90/100/100/180/19
CoughRespiratory, thoracic and mediastinal disorders0/191/200/100/90/100/101/181/19
NauseaGastrointestinal disorders0/190/200/100/90/100/101/180/19

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 postdose safety assessment.

Age, Customized
Age, Customized(Participants)Arm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)Total
18 to 65 years10105555101060
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Arm 1: 11 mg Lenvatinib Suspension in WaterArm 1: 11 mg Lenvatinib Capsule With WaterArm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water)Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice)Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours)Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours)Total
Male9753335742
Female1302225318
08

Study locations

1 site
  • Las Vegas, Nevada, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2015
First posted
Jun 8, 2016
Start
Aug 2014
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Mar 14, 2019
Last update
Mar 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02792829
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 8, 2016
Start date
Aug 2014
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Mar 14, 2019
Last update
Mar 14, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion